# Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

> **NCT03067051** · PHASE1,PHASE2 · RECRUITING · sponsor: **SpectraCure AB** · enrollment: 66 (estimated)

## Conditions studied

- Recurrent Prostate Cancer

## Interventions

- **DRUG:** Verteporfin
- **DEVICE:** SpectraCure P18 System

## Key facts

- **NCT ID:** NCT03067051
- **Lead sponsor:** SpectraCure AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-03-21
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03067051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03067051, "Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03067051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*